

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Takeda Pharmaceuticals International AG</u> (Last) (First) (Middle) THURGAUERSTRASSE 130, 8152 GLATTPARK-OPFIKON (Street) ZURICH V8 8152 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Myovant Sciences Ltd. [MYOV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/19/2018	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/19/2018		S		7,420,625	D ⁽¹⁾⁽²⁾	\$18.67	0 ⁽¹⁾⁽²⁾	D	
Common Stock	03/19/2018		P		7,420,625	A ⁽¹⁾⁽²⁾	\$18.67	7,420,625 ⁽¹⁾⁽²⁾	I	By Millennium Pharmaceuticals, Inc. ⁽¹⁾⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Takeda Pharmaceuticals International AG
 (Last) (First) (Middle)
 THURGAUERSTRASSE 130,
 8152 GLATTPARK-OPFIKON
 (Street)
 ZURICH V8 8152
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
TAKEDA PHARMACEUTICAL CO LTD
 (Last) (First) (Middle)
 12-10, NIHONBASHI 2-CHOME, CHUO-KU
 (Street)
 TOKYO M0 103-8668
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Takeda A/S

(Last)	(First)	(Middle)
DYBENDAL ALLE 10, 2630		
_____ (Street)		
TAASTRUP G7		
_____ (City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Takeda Europe Holdings B.V.		
_____ (Last) (First) (Middle)		
JUPITERSTRAAT 250, 2132 HK		
_____ (Street)		
HOOFDDORP P7		
_____ (City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Takeda Pharma A/S		
_____ (Last) (First) (Middle)		
DYBENDAL ALLE 10,2630		
_____ (Street)		
TAASTRUP G7		
_____ (City) (State) (Zip)		

Explanation of Responses:

1. On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited ("TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BY (Netherlands) ("TEHBV"); TPAS is owned by Takeda A/S (Denmark) ("T AS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV. TEHBV is wholly-owned by TPC.

2. (Continued from Footnote 1) Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.

Remarks:

Exhibit List: Exhibit 24.1 Power of Attorney for Takeda Pharmaceuticals International AG; Exhibit 24.2 Power of Attorney for Takeda Pharmaceuticals Company Limited; Exhibit 24.3 Power of Attorney for Takeda A/S (Denmark); Exhibit 24.4 Power of Attorney for Takeda Europe Holdings B.V. (Netherlands); Exhibit 24.5 Power of Attorney for Takeda Pharma A/S (Denmark).

/s/ Chad Diehl, Attorney in Fact	03/21/2018
/s/ Chad Diehl, Attorney in Fact	03/21/2018
/s/ Chad Diehl, Attorney in Fact	03/21/2018
/s/ Chad Diehl, Attorney in Fact	03/21/2018
/s/ Chad Diehl, Attorney in Fact	03/21/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that Takeda Pharmaceuticals International AG, a public limited company incorporated under the laws of Switzerland, registered with the commercial register of Canton Zurich under CHE-113.444.401 and with business address at Thurgauerstrasse 130, 8152 Glattpark - Opfikon (Zurich) ("TPIZ") hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as the TPIZ's true and lawful attorney-in-fact to:

- (1) prepare, execute in TPIZ's name and on TPIZ's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling TPIZ to make electronic filings with the SEC of Reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) prepare and file on behalf of TPIZ any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that TPIZ may be required to file with the SEC pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to TPIZ's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned (directly or indirectly) by TPIZ (each an "Portfolio Company" and collectively "Portfolio Companies");
- (3) do and perform any and all acts for and on behalf of TPIZ which may be necessary or desirable to complete and execute any such Reports, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (4) complete for and on behalf of TPIZ, execute in TPIZ's name and on TPIZ's behalf, and submit to the requestor thereof, any questionnaires, documents or other materials that are requested in connection with any (i) equity or debt offering by a Portfolio Company and (ii) exercise by TPIZ of voting or proxy rights in connection with TPIZ's equitiownership of any Portfolio Company; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, TPIZ, it being understood that the documents executed by such attorney-in-fact on behalf of TPIZ pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

TPIZ hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as TPIZ might or could do if the legal representatives of TPIZ were personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. TPIZ acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of TPIZ, are not assuming nor relieving any of TPIZ's responsibilities to comply with Section 13 or Section 16 of the Exchange Act. TPIZ acknowledges that none of the foregoing attorneys-in-fact assume (i) any liability for TPIZ's responsibility to comply with the requirements of the Act or the Exchange Act, (ii) any liability of TPIZ for any failure to comply with such requirements or (iii) any obligation or liability of TPIZ for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until TPIZ is no longer required to file any Reports with respect to TPIZ's ownership of, or transactions in, the securities of Portfolio Companies, unless earlier revoked by TPIZ at any time at its sole discretion. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to serve as an employee of Takeda Pharmaceutical Company Limited (Japan) or one of its subsidiaries.

[Signature page follows]

IN WITNESS WHEREOF, TPIZ has caused this Power of Attorney to become effective as of the date set forth below.

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

By: /s/ Nils Kjaergaard

Name: ppa. Nils Kjaergaard

Title: VP. General Counsel Europe and Canada

Date:

TAKEDA PHARMACEUTICALS INTERNATIONAL AG

By: /s/ Mirjam von Zedtwitz

Name: Takeda Pharmaceuticals International AG
ppa. Mirjam von Zedtwitz

Title: Associate General Counsel Corporate

Date:

POWER OF ATTORNEY

Know all by these present, that Takeda Pharmaceutical Company Limited (the "Reporting Person") hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as the Reporting Person's true and lawful attorney-in-fact to:

- (1) prepare, execute in the Reporting Person's name and on the Reporting Person's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the Reporting Person to make electronic filings with the SEC of Reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) prepare and file on behalf of the Reporting Person any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that the Reporting Person may be required to file with the SEC pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to the Reporting Person's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned (directly or indirectly) by the Reporting Person ("Portfolio Companies");
- (3) do and perform any and all acts for and on behalf of the Reporting Person which may be necessary or desirable to complete and execute any such Reports, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (4) complete for and on behalf of the Reporting Person, execute in the Reporting Person's name and on the Reporting Person's behalf, and submit to the requestor thereof, any questionnaires, documents or other materials that are requested in connection with any (i) equity or debt offering by a Portfolio Company and (ii) exercise by the Reporting Person of voting or proxy rights in connection with the Reporting Person's equity ownership of any Portfolio Company; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the Reporting Person, it being understood that the documents executed by such attorney-in-fact on behalf of the Reporting Person pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The Reporting Person hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the Reporting Person might or could do if the legal representatives of the Reporting Person were personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The Reporting Person acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the Reporting Person, are not assuming nor relieving any of the Reporting Person's responsibilities to comply with Section 13 or Section 16 of the Exchange Act. The Reporting Person acknowledges that none of the foregoing attorneys-in-fact assume (i) any liability for the Reporting Person's responsibility to comply with the requirements of the Act or the Exchange Act, (ii) any liability of the Reporting Person for any failure to comply with such requirements or (iii) any obligation or liability of the Reporting Person for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, the securities of Portfolio Companies, unless earlier revoked by the Reporting Person at any time at its sole discretion. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to serve as an employee of a subsidiary of the Reporting Person.

[Signature page follows]

IN WITNESS WHEREOF, the Reporting Person has caused this Power of Attorney to become effective as of the date set forth below.

TAKEDA PHARMACEUTICAL COMPANY LIMITED

By: /s/ James Kehoe

Name: James Kehoe

Title: Chief Financial Officer

Date: November 27, 2017

POWER OF ATTORNEY

Know all by these present, that Takeda A/S, a stock limited company incorporated under the laws of Denmark, and with business address at Dybendal Alle 10, 2630 Taastrup, Denmark ("Takeda A/S") hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda A/S 's true and lawful attorney-in-fact to:

- (1) prepare, execute in Takeda A/S's name and on Takeda A/S's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling Takeda A/S to make electronic filings with the SEC of Reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- {2} prepare and file on behalf of Takeda A/S any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that Takeda A/S may be required to file with the SEC pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to Takeda A/S's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned {directly or indirectly} by Takeda A/S {each an "Portfolio Company" and collectively "Portfolio Companies"};
- (3) do and perform any and all acts for and on behalf of Takeda A/S which may be necessary or desirable to complete and execute any such Reports, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (4) complete for and on behalf of Takeda A/S, execute in Takeda A/S's name and on Takeda A/S's behalf, and submit to the requestor thereof, any questionnaires, documents or other materials that are requested in connection with any (i) equity or debt offering by a Portfolio Company and (ii) exercise by Takeda A/S of voting or proxy rights in connection with Takeda A/S's equity ownership of any Portfolio Company; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, Takeda A/S, it being understood that the documents executed by such attorney-in-fact on behalf of Takeda A/S pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

Takeda A/S hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as Takeda A/S might or could do if the legal representatives of Takeda A/S were personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. Takeda A/S acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of Takeda A/S, are not assuming nor relieving any of Takeda A/S's responsibilities to comply with Section 13 or Section 16 of the Exchange Act. Takeda A/S acknowledges that none of the foregoing attorneys-in-fact assume (i) any liability for Takeda A/S's responsibility to comply with the requirements of the Act or the Exchange Act, (ii) any liability of Takeda A/S for any failure to comply with such requirements or (iii) any obligation or liability of Takeda A/S for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until Takeda A/S is no longer required to file any Reports with respect to Takeda A/S's ownership of, or transactions in, the securities of Portfolio Companies, unless earlier revoked by Takeda A/S at any time at its sole discretion. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to serve as an employee of Takeda Pharmaceutical Company Limited (Japan) or one of its subsidiaries.

[Signature page follows]

IN WITNESS WHEREOF, Takeda A/S has caused this Power of Attorney to become effective as of the date set forth below.

TAKEDA A/S

By: /s/ Patrik Forsell

Name: Patrik Forsell

Title: Managing Director

Date: 12/12 - 2017

POWER OF ATTORNEY

Know all by these present, that Takeda Europe Holdings B.V., a private limited liability company incorporated under the laws of the Netherlands, and with a business address at Jupiterstraat 250, 2132 HK Hoofddorp, Netherlands ("Takeda Europe") hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda Europe's true and lawful attorney-in-fact to:

- (1) prepare, execute in Takeda Europe's name and on Takeda Europe's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling Takeda Europe to make electronic filings with the SEC of Reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) prepare and file on behalf of Takeda Europe any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that Takeda Europe may be required to file with the SEC pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to Takeda Europe's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned (directly or indirectly) by Takeda Europe (each an "Portfolio Company" and collectively "Portfolio Companies");
- (3) do and perform any and all acts for and on behalf of Takeda Europe which may be necessary or desirable to complete and execute any such Reports, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (4) complete for and on behalf of Takeda Europe, execute in Takeda Europe's name and on Takeda Europe's behalf, and submit to the requestor thereof, any questionnaires, documents or other materials that are requested in connection with any (i) equity or debt offering by a Portfolio Company and (ii) exercise by Takeda Europe of voting or proxy rights in connection with Takeda Europe's equity ownership of any Portfolio Company; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, Takeda Europe, it being understood that the documents executed by such attorney-in-fact on behalf of Takeda Europe pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

Takeda Europe hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as Takeda Europe might or could do if the legal representatives of Takeda Europe were personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. Takeda Europe acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of Takeda Europe, are not assuming nor relieving any of Takeda Europe's responsibilities to comply with Section 13 or Section 16 of the Exchange Act. Takeda Europe acknowledges that none of the foregoing attorneys-in-fact assume (i) any liability for Takeda Europe's responsibility to comply with the requirements of the Act or the Exchange Act, (ii) any liability of Takeda Europe for any failure to comply with such requirements or (iii) any obligation or liability of Takeda Europe for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until Takeda Europe is no longer required to file any Reports with respect to Takeda Europe's ownership of, or transactions in, the securities of Portfolio Companies, unless earlier revoked by Takeda Europe at any time at its sole discretion. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to serve as an employee of Takeda Pharmaceutical Company Limited (Japan) or one of its subsidiaries.

[Signature page follows]

IN WITNESS WHEREOF, Takeda Europe has caused this Power of Attorney to

become effective as of the date set forth below.

TAKEDA EUROPE HOLDINGS B.V.

By: /s/ Remco van Rhoon

Name: Remco van Rhoon

Title: Managing Director

Date: 29 November 2017

TAKEDA EUROPE HOLDINGS B.V.

By: /s/ Manoj Bhojwani

Name: Manoj Bhojwani

Title: Managing Director

Date: 4/Dec/2017

POWER OF ATTORNEY

Know all by these present, that Takeda Pharma A/S, a stock limited company incorporated under the laws of Denmark, and with business address at Dybendal Alle 10, 2630 Taastrup, Denmark ("Takeda Pharma A/S") hereby constitutes and appoints each of Paul Sundberg, Chad Diehl and Brett Budzinski, signing singly, as Takeda Pharma A/S's true and lawful attorney-in-fact to:

- (1) prepare, execute in Takeda Pharma A/S's name and on Takeda Pharma A/S's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling Takeda Pharma A/S to make electronic filings with the SEC of Reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) prepare and file on behalf of Takeda Pharma A/S any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 3, Form 4 and Form 5) that Takeda Pharma A/S may be required to file with the SEC pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to Takeda Pharma A/S's ownership of, or transactions in, the securities of any entity whose securities are beneficially owned (directly or indirectly) by Takeda Pharma A/S (each an "Portfolio Company" and collectively "Portfolio Companies");
- (3) do and perform any and all acts for and on behalf of Takeda Pharma A/S which may be necessary or desirable to complete and execute any such Reports, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (4) complete for and on behalf of Takeda Pharma A/S, execute in Takeda Pharma A/S's name and on Takeda Pharma A/S's behalf, and submit to the requestor thereof, any questionnaires, documents or other materials that are requested in connection with any (i) equity or debt offering by a Portfolio Company and (ii) exercise by Takeda Pharma A/S of voting or proxy rights in connection with Takeda Pharma A/S's equity ownership of any Portfolio Company; and
- (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, Takeda Pharma A/S, it being understood that the documents executed by such attorney-in-fact on behalf of Takeda Pharma A/S pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

Takeda Pharma A/S hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as Takeda Pharma A/S might or could do if the legal representatives of Takeda Pharma A/S were personally present, hereby ratifying and confirming all that such attorney-in-fact shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. Takeda Pharma A/S acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of Takeda Pharma A/S, are not assuming nor relieving any of Takeda Pharma A/S's responsibilities to comply with Section 13 or Section 16 of the Exchange Act. Takeda Pharma A/S acknowledges that none of the foregoing attorneys-in-fact assume (i) any liability for Takeda Pharma A/S's responsibility to comply with the requirements of the Act or the Exchange Act, (ii) any liability of Takeda Pharma A/S for any failure to comply with such requirements or (iii) any obligation or liability of Takeda Pharma A/S for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until Takeda Pharma A/S is no longer required to file any Reports with respect to Takeda Pharma A/S's ownership of, or transactions in, the securities of Portfolio Companies, unless earlier revoked by Takeda Pharma A/S at any time at its sole discretion. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to serve as an employee of Takeda Pharmaceutical Company Limited (Japan) or one of its subsidiaries.

[Signature page follows]

IN WITNESS WHEREOF, Takeda Pharma A/S has caused this Power of Attorney to

become effective as of the date set forth below.

TAKEDA PHARMA A/S

By: /s/ Patrik Forsell

Name: Patrik Forsell

Title: Managing Director

Date: 12/12-2017
